Andreas Strüngmann

Andreas Strüngmann
Born	1950 Germany
Occupation(s)	Medical doctor, businessman
Known for	Co-founder of Hexal AG, investments in biotech and pharmaceutical sectors

Andreas Strüngmann (born 1950) is a German medical doctor and billionaire businessman who co-established the generic pharmaceutical company Hexal AG in 1986, reaching $1.6 billion in revenue by 2004. Together with his identical twin brother, Thomas Strüngmann, he accumulated wealth mainly through strategic investments in the biotech and pharmaceutical sectors. The siblings jointly oversee family holdings valued at approximately $30 billion through their unified family office.

Career

In 2004, the Strüngmann twins, via Santo Holding, purchased an 89.6% share in Südwestbank from DZ Bank, which they later divested in 2017 to BAWAG for a confidential amount.

The following year, February 2005, they divested Hexal along with a 67.7% interest in the U.S.-based Eon Labs to Novartis for $7.5 billion. This transaction positioned Novartis’s subsidiary, Sandoz, as the largest generic pharmaceutical company worldwide. Subsequently, Andreas assumed an executive position at Sandoz, managing operations across Europe, Africa, and the Asia-Pacific region.

In 2008, through their investment vehicle Athos, the brothers financed 25% of a capital increase at Conergy. That same year, they provided €136.5 million in a €150 million financing round that facilitated the establishment of BioNTech. By 2023, their ownership via AT Impf accounted for a 43.5% stake in BioNTech, valued near $14 billion.

In 2014, Santo Holding partnered with EQT AB to acquire Siemens Audiology Solutions from Siemens for €2.2 billion, leading Siemens to abandon its plans for an initial public offering.

Personal life

Strüngmann divides his time between residences in Tegernsee and South Africa, is married, and has two children. In 2007, he and his wife established the Andreas and Susan Struengmann Foundation aimed at supporting educational projects within the Western Cape.